Medtronic, Fitbit partner to integrate monitoring technology

The medical technology company Medtronic and Fitbit, known for its wearable activity trackers, have announced a partnership that will integrate their technologies to allow patients with type 2 diabetes to monitor both exercise and blood glucose in one mobile app.

The new app, called iPro2 myLog, will use inputs from Medtronic’s iPro2 CGM system and the Fitbit activity tracker.

“By creating a connection between physical activity and glucose levels, our iPro2 myLog mobile app solution provides new tools and insights, so that physicians can optimize therapy and patients can better understand how to manage their diabetes” Laura Stoltenberg, vice president and general manager of non-intensive diabetes therapies at Medtronic, said in a press release. “By helping people with diabetes implement lasting lifestyle changes, this partnership underscores our commitment to transforming diabetes care, together, for greater freedom and better health.”

Users will be able to access their physical activity data along with their CGM readings in one interface to show how exercise affects glucose levels. They will also be able to easily share this information with their health care provider, according to the release.

“We believe the integration of wearable technology with professional diagnostic tools can provide a more accurate and actionable view of a patient’s physical activity,” Adam Pellegrini, vice president of digital health for Fitbit said in the release. “By partnering with Medtronic, we are able to bring the power of Fitbit’s automatic activity tracking together with continuous glucose monitoring, allowing patients and providers to have a more informed conversation.”